Table 1.
Clinical parameters of the patients involved in the study
| SR | AF | |
|---|---|---|
| Patients, n | 58 | 33 |
| Gender, m/f | 50/8 | 28/5 |
| Age, year | 65.3 ± 1.5 | 70.8 ± 1.4 |
| Body mass index, kg/m2 | 27.7 ± 0.5 | 29.5 ± 0.7 |
| CAD, n (%) | 45 (78%) | 7 (21%) |
| MVD/AVD, n (%) | 7 (12%) | 16 (48%) |
| CAD + MVD/AVD, n (%) | 6 (10%) | 10 (30%) |
| Hypertension, n | 54 (93%) | 32 (97%) |
| Diabetes, n | 23 (40%) | 17 (52%) |
| Hyperlipidemia, n | 50 (86%) | 26 (79%) |
| LVEF, % | 51.4 ± 1.9 | 48.1 ± 2.3 |
| Digitalis, n (%) | 3 (5%) | 13 (39%) |
| ACE inhibitors, n (%) | 37 (64%) | 18 (54%) |
| AT1 blockers, n (%) | 10 (17%) | 7 (21%) |
| β‐blockers, n (%) | 45 (78%) | 28 (85%) |
| Ca2+‐antagonists, n (%) | 13 (22%) | 11 (33%) |
| Diuretics, n (%) | 20 (34%) | 26 (79%) |
| Nitrates, n (%) | 5 (9%) | 2 (6%) |
| Lipid‐lowering drugs, n (%) | 47 (81%) | 20 (61%) |
SR, sinus rhythm; AF, chronic atrial fibrillation; CAD, coronary artery disease; MVD, mitral valve disease requiring valve replacement; AVD, aortic valve disease requiring valve replacement; LVEF, left ventricular ejection fraction; ACE, angiotensin‐converting enzyme; AT, angiotensin receptor.